UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

February 6, 2014

Date of Report (Date of earliest event reported)

 

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

  

Nevada   001-15697   22-3542636
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

 

(201) 750-2646

(Registrant’s telephone number, including area code)

 

 
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On February 7, 2014, Elite Pharmaceuticals, Inc. (the “Company”) and Elite Laboratories, Inc., its wholly-owned subsidiary, amended the following convertible promissory notes: (i) an August 1, 2013 Secured Convertible Note to Mikah Pharma LLC (“Mikah”) due August 1, 2016 in the principal amount of $10,000,000 (the “Mikah Note”), and (ii) a November 21, 2013 Convertible Note to Jerry Treppel due November 21, 2016 in the principal amount of $600,000 (the “Treppel Note” and, together with the Mika Note, the “Notes”). Mikah is owned by the Company’s CEO and President and Mr. Treppel is a director of the Company. Generally, the Notes were amended to make them convertible into shares of the Company’s newly created Series I Convertible Preferred Stock. For a description of this new series of preferred stock, please see “Item 5.03” below. The Mikah Note also was amended to make it immediately exercisable.

 

The foregoing description of the Amendments to the Notes is qualified in its entirety by reference to the full text of the Amendments, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and are incorporated herein in their entirety by reference.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

On February 7, 2014, Mikah converted the entire Mikah Note into 100 shares of I Preferred Stock and Treppel converted the entire Treppel Note into 4.242 shares of the Company’s Series I Convertible Preferred Stock. Please see Item 5.03, below. We relied on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On February 6, 2014, the Company filed a Certificate of Designations (the “COD”) with the Nevada Secretary of State designating a new series of convertible preferred stock - Series I Preferred Stock (the “I Preferred Stock”) and setting forth the various rights, preferences, restrictions and other matters related to the I Preferred Stock. 500 shares were designated as I Preferred Stock. Each share of I Preferred Stock has a Stated Value of $100,000 and is convertible at the option of the holder thereof (the “Holder”) into such number of shares of Common Stock determined by dividing the Stated Value of such share of I Preferred Stock by the Conversion Price (currently $0.07, subject to adjustment pursuant to the terms of the COD). Each share of I Preferred is entitled to vote along with the holders of Common Stock and each share is entitled to votes equal to the number of shares of Common Stock into which they are convertible. Holders are entitled to dividends if and when declared in an amount equal to the dividend he or she would have been entitled to receive upon conversion, in full, of one share of Series I Preferred in to Common Stock. Upon any liquidation, dissolution or winding-up of the Company, each Holder is entitled to receive, pari passu and pro rata with the holders of Common Stock, out of the assets of the Company an amount equal to the amount distributable with regard to the number of shares of Common Stock into which the shares of Series I Preferred Stock held by the Holder are convertible.

 

1
 

 

The foregoing description of the Certificate of Designations is qualified in its entirety by reference to the full text of the Certificate of Designations, a copy of which is attached hereto as Exhibit 4.1 and incorporated herein in its entirety by reference.

 

Item 9.01.         Financial Statements and Exhibits.

 

(c) Exhibits:

 

  4.1 Certificate of Designations of the Series I Preferred Stock.
  4.2 Form of Series I Preferred Stock Certificate.
10.1 February 7, 2014 Amendment to August 1, 2013 Secured Convertible Note from the Company to Mikah Pharma LLC due August 1, 2016.
10.2 February 7, 2014 Amendment to November 21, 2013 Secured Convertible Note from the Company to Jerry Treppel due November 21, 2016.

 

2
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 7, 2014

 

    ELITE PHARMACEUTICALS, INC.
     
  By: s/ Nasrat Hakim
    Nasrat Hakim, President and CEO

 

3

 

CERTIFICATE OF DESIGNATION

 

of

 

SERIES I CONVERTIBLE PREFERRED STOCK

 

of

 

ELITE PHARMACEUTICALS, INC.,

 

(Pursuant to Section 78.1955 of the
Nevada Revised Statutes)

 

 

 

Elite Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Nevada (hereinafter called the “ Corporation ”), hereby certifies that the following resolution was adopted by the board of directors of the Corporation as required by Section 78.1955 of the Nevada Revised Statutes at a meeting of the Directors on January 29, 2014:

 

RESOLVED , that pursuant to the authority granted to and vested in the board of directors of the Corporation (the “ Board ”) in accordance with the provisions of the Articles of Incorporation of the Corporation, as currently in effect, the Board hereby creates a series of Preferred Stock, par value $0.01 per share (the “ Preferred Stock ”), of the Corporation and hereby states the designation and number of shares, and fixes the relative rights, preferences, and limitations thereof as follows (with all terms not otherwise defined having the meaning set forth in Section 10 of the Certificate of Designation):

 

Series I Convertible Preferred Stock:

 

Section 1.           Designation, Amount and Stated Value . The shares of such series shall be designated as “Series I Convertible Preferred Stock” (the “ Series I Preferred Stock ”) and the number of shares constituting the Series I Preferred Stock shall be five hundred (500) and stated value of each share of Series I Preferred Stock shall be equal to $100,000 (one hundred thousand dollars) (the " Stated Value "). Such number of shares may be increased or decreased by resolution of the board of directors; provided , that no decrease shall reduce the number of shares of Series I Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by the Corporation convertible into Series I Preferred Stock.

 

Section 2.           Dividends and Distributions .

 

(a)          So long as any Series I Preferred Stock shall remain outstanding, the Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends payable pursuant to the Series C Preferred Stock or any other shares of any series of Preferred Stock (or any similar stock) ranking prior and superior to the Series I Preferred Stock with respect to dividends) unless the Holder shall first receive, or simultaneously receive, a dividend on each outstanding share of Series I Preferred Stock in an amount equal to the dividend the Holder would have been entitled to receive upon conversion, in full, of one share of Series I Preferred Stock immediately prior to the record date for determination of holders entitled to receive such dividend.

 

1
 

 

Section 3.           Voting Rights . The Holders of shares of Series I Preferred Stock shall have the following voting rights:

 

(a)          On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), the Holder shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series I Preferred Stock held by the Holder are convertible as of the record date for determining the stockholders entitled to vote on such matter.

 

(b)          Except as otherwise provided herein, in any other certificate of designations creating a series of Preferred Stock or any similar stock, or by law, the Holders and the holders of shares of Common Stock and any other capital stock of the Corporation having general voting rights shall vote together as one class on all matters submitted to a vote of stockholders of the Corporation.

 

(c)          Except as set forth herein, or as otherwise provided by law, Holders shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for taking any corporate action.

 

Section 4.           Conversion .

 

(a)           Conversions at Option of the Holder . Each share of Series I Preferred Stock shall be convertible into shares of Common Stock (subject to the limitations set forth in Section 4(c)), at the option of the Holder, at any time, by dividing the Stated Value of such share of Series I Preferred Stock by the Conversion Price.

 

(b)           Conversion Price . The conversion price for the Series I Preferred Stock shall equal U.S.$0.07, subject to adjustment herein (the “ Conversion Price ”).

 

(c)           Conversion Restrictions . Anything set forth herein to the contrary notwithstanding:

 

(i)          If the Corporation is listed on a Trading Market that is a National Market and the Corporation has not previously obtained Shareholder Approval, and such National Market requires Shareholder Approval then the Corporation may not issue in excess of the Issuable Maximum upon conversions of the Series I Preferred Stock. If on any Conversion Date: (A) the aggregate number of shares of Common Stock that would then be issuable upon a conversion by the Holder of Series I Preferred Stock would exceed the Issuable Maximum, and (B) the Corporation shall not have previously obtained Shareholder Approval, then the Corporation shall issue to the converting Holder a number of shares of Common Stock up to the Issuable Maximum. The Corporation and the Holder understand and agree that shares of Common Stock issued to and then held by the Holder as a result of conversions of the Note shall not be entitled to cast votes on any resolution to obtain Shareholder Approval pursuant hereto.

 

2
 

 

(ii)         If, upon any Conversion Date there is not a sufficient number of authorized shares of Common Stock (that are not issued, outstanding or reserved for issuance) available to effect the entire conversion, such conversion shall not exceed the Issuable Maximum; however, the Corporation shall use its best efforts to obtain Shareholder Approval within four (4) months of such Conversion Date to permit the balance of the conversion.

 

(d)           Mechanics of Conversion .

 

(i)          A Holder shall effect conversions under Section 4(a) by delivering to the Corporation a Conversion Notice. Promptly after receipt by the Corporation of a Conversion Notice, the Corporation shall (A) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in the name of the Holder a certificate for the Conversion Shares or (B) instruct the Corporation’s transfer agent to issue such Conversion Shares in book entry form and promptly notify Holder of same. The Holder shall be deemed to have become holder of record of such Conversion Shares as of the Conversion Date.

 

(ii)         Conversion Shares shall be restricted securities, not transferable unless registered under the Securities Act of 1933 or such transfer is permitted pursuant to an exemption from such registration under such Act.

 

(e)           Fractional Shares . Upon a conversion hereunder, the Corporation shall not be required to issue stock certificates representing fractions of shares of Common Stock, but may if otherwise permitted, make a cash payment in respect of any final fraction of a share.

 

(f)           Transfer Taxes . The issuance of certificates for Conversion Shares on conversion of the Series I Preferred Stock shall be made without charge to the Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Holder of such shares of Series I Preferred Stock so converted and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.

 

Section 5.        Reacquired Shares . Any shares of Series I Preferred Stock purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and cancelled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but unissued shares of Preferred Stock and may be reissued as part of a new series of Preferred Stock subject to the conditions and restrictions on issuance set forth herein, in the Articles of Incorporation, or in any other certificate of designations creating a series of Preferred Stock or any similar stock or as otherwise required by law.

 

3
 

 

Section 6.           Liquidation, Dissolution or Winding Up .

 

(a)          Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “ Liquidation ”), each Holder shall be entitled to receive for each share of Series I Preferred Stock, pari passu and pro rata with the holders of Common Stock, out of the assets, whether capital or surplus, of the Corporation an amount equal to the amount distributable with regard to the number of whole shares of Common Stock into which the shares of Series I Preferred Stock held by the Holder are convertible as of the date of the Liquidation.

 

(b)          In the event, however, that there are not sufficient assets available to permit payment in full of the Liquidation Amount, then remaining assets shall be distributed ratably to the Holders and the holders of the Common Stock, in proportion to their Common Stock Equivalency.

 

Section 7.           Certain Adjustments .

 

(a)           Stock Dividends and Splits . If the Corporation, at any time while the Series I Preferred Stock is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, the Existing Preferred Stock); (B) subdivides outstanding shares of Common Stock into a larger number of shares; (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (D) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

4
 

 

(b)           Subsequent Dilutive Issuances . If the Corporation or any Subsidiary thereof, at any time while this Series I Preferred Stock is outstanding, sells or grants any option to purchase or sells or grants any right to reprice its securities (other than any Common Stock or Common Stock Equivalents in connection with an Exempt Issuance), entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then applicable Conversion Price (any such issuance, a “ Dilutive Issuance ”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the then applicable Conversion Price, such issuance shall be deemed to have occurred for less than the then applicable Conversion Price on such date of the Dilutive Issuance), then the then applicable Conversion Price shall be reduced to a price determined by multiplying the then applicable Conversion Price by a fraction, the numerator of which is the sum of (i) the number of shares of Common Stock issued and outstanding immediately prior to the Dilutive Issuance plus (ii) the number of shares of Common Stock issuable upon conversion or exercise of Common Stock Equivalents issued and outstanding immediately prior to the Dilutive Issuance plus (iii) the number of shares of Common Stock which the offering price for such Dilutive Issuance would purchase at the then applicable Conversion Price, and the denominator of which shall be the sum of (1) the number of shares of Common Stock issued and outstanding immediately prior to the Dilutive Issuance plus (2) the number of shares of Common Stock issuable upon conversion or exercise of Common Stock Equivalents issued and outstanding immediately prior to the Dilutive Issuance plus (3) the number of shares of Common Stock so issued or issuable in connection with the Dilutive Issuance. Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of any issuance as to which the Holder has provided its written approval. The Corporation shall notify the Holder in writing, no later than five (5) Business Days following a Dilutive Issuance, indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the “ Dilutive Issuance Notice ”). For purposes of clarification, whether or not the Corporation provides a Dilutive Issuance Notice pursuant to this Section 7(b), upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Conversion Shares based upon the adjusted Conversion Price on or after the date of such Dilutive Issuance, regardless of whether the Holder accurately refers to the adjusted Conversion Price in the Notice of Conversion.

 

(c)           Subsequent Dividend Issuances . If the Corporation, at any time while the Series I Preferred Stock is outstanding, shall issue shares of Common Stock in lieu of cash in satisfaction of its dividend obligations on shares of outstanding Existing Preferred Stock in accordance with the Series C Certificate (any such issuance, a “ Dividend Issuance ”), then the then applicable Conversion Price shall be reduced to a price equal to (i) the aggregate Stated Value of Series I Preferred Stock then outstanding divided by (ii) the product of (x) aggregate number of Conversion Shares issuable upon conversion of the then outstanding Series I Preferred Stock immediately prior to Dividend Issuance multiplied by (y) the sum of one plus a fraction with: (A) a numerator equal to (I) the number of outstanding shares of Common Stock immediately after giving effect to the Dividend Issuance (assuming conversion of all Existing Preferred Stock in accordance with the Series C Certificate, but not the Series I Preferred Stock) minus (II) the number of outstanding shares of Common Stock immediately prior to the Dividend Issuance (assuming conversion of all Existing Preferred Stock in accordance with the Series C Certificate, but not the Series I Preferred Stock); and (B) a denominator equal to the number of outstanding shares of Common Stock immediately prior to the Dividend Issuance (assuming conversion of all Existing Preferred Stock in accordance with the Series C Certificate, but not the Series I Preferred Stock). The Corporation shall notify the Holder in writing following a Dividend Issuance, indicating therein the occurrence of the applicable Dividend Issuance triggering such adjustment and the calculation of such adjusted Conversion Price (such notice, the “ Dividend Issuance Notice ”). For purposes of clarification, whether or not the Corporation provides a Dividend Issuance Notice pursuant to this Section 7(c), upon the occurrence of any Dividend Issuance, the Holder is entitled to receive a number of Conversion Shares based upon the adjusted Conversion Price on or after the date of such Dividend Issuance, regardless of whether the Holder accurately refers to the adjusted Conversion Price in the Notice of Conversion.

 

5
 

 

(d)           Pro Rata Distributions . If the Corporation, at any time while there are any shares of Series I Preferred Stock issued or outstanding, distributes to all holders of Common Stock (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock described in Sections 7(b) or 7(c)), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, “Distributed Property”), then, at the request of any Holder delivered before the 90th day after the record date fixed for determination of stockholders entitled to receive such distribution, the Corporation will deliver to any such Holder, within five (5) Trading Days after such request (or, if later, on the effective date of such distribution), the Distributed Property that any such Holder would have been entitled to receive in respect of the Conversion Shares for which the shares of Series I Preferred Stock could have been converted immediately prior to such record date. If such Distributed Property is not delivered to any such Holder pursuant to the preceding sentence, upon any conversion by any such Holder of his or her shares of Series I Preferred Stock that occurs after such record date, any such Holder shall be entitled to receive, in addition to the Conversion Shares otherwise issuable upon such conversion, the Distributed Property that any such Holder would have been entitled to receive in respect of such number of Conversion Shares had any such Holder been the record holder of such Conversion Shares immediately prior to such record date.

 

(e)           Fundamental Changes . If, at any time while there are any shares of Series I Preferred Stock issued or outstanding, (i) the Corporation effects any merger or consolidation of the Corporation with or into another Person (other than the Holder), (ii) the Corporation or the Subsidiary effects any sale of all or substantially all of either of their assets in one or more transactions (other than the Holder), (iii) any tender offer or exchange offer (whether by the Corporation or another Person other than the Holder) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (iv) the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock described in Section 7(a)) (in any such case, a “ Fundamental Change ”), then upon any subsequent conversion of Series I Preferred Stock, any Holder thereof shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion absent such Fundamental Change, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Change if it had been, immediately prior to such Fundamental Change, the holder of one share of Common Stock (the “ Alternate Consideration ”). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Change, then such Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of shares of such Holders Series I Preferred Stock following such Fundamental Change.

 

6
 

 

(f)           Calculations . All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Corporation, and the disposition of any such shares shall be considered an issue or sale of Common Stock.

 

(g)           Notice of Adjustments . Upon the occurrence of each adjustment pursuant to this Section 7, the Corporation at its expense will promptly compute such adjustment in accordance with the terms hereof and prepare and deliver to the Holder a certificate describing in reasonable detail such adjustment and the transactions giving rise thereto, including all facts upon which such adjustment is based.

 

Section 8.            No Redemption . The shares of Series I Preferred Stock shall not be redeemable.

 

Section 9.           Rank . The Series I Preferred Stock shall rank, with respect to the payment of dividends and the distribution of assets, junior to all series of any other class of the Corporation’s Preferred Stock and pari passu with respect to the Corporation’s Common Stock.

 

Section 10.         Definitions .

 

(a)           “ As Converted Common Stock ” means the sum of the total number of shares of Common Stock issued and outstanding plus the total number of shares of Common Stock into which all issued and outstanding shares of Series I Preferred Stock is convertible (regardless of whether there are sufficient authorized but unissued shares of Common Stock to issue upon such conversion).

 

(b)          “ Certificate of Designations ” means the Certificate of Designation of Series I Convertible Preferred Stock.

 

(c)          “ Common Stock ” means the Corporation’s common stock, par value $0.001 per share.

 

(d)           Common Stock Equivalency ” means (i) for holders of Common Stock, the percentage obtained by dividing the number of shares of Common Stock owned by such holders by the As Converted Common Stock, and (ii) for the Holders, the percentage obtained by dividing the number of shares of Common Stock into which such Holder’s Series I Preferred Stock is convertible (regardless of whether there are sufficient authorized but unissued shares of Common Stock to issue upon such conversion) by the As Converted Common Stock.

 

(e)          “ Conversion Date ” means the date any Conversion Notice is received by the Corporation pursuant to Section 4(d).

 

(f)          “ Conversion Notice ” means a written instruction from a Holder to the Corporation stating the Holder’s conversion of all or a portion of such Holder’s shares of Series I Preferred Stock and indicating the number of shares of Series I Preferred Stock being so converted, with the form of such instructions attached hereto as Annex A.

 

7
 

 

(g)          “ Conversion Price ” shall have the meaning set forth in Section 4(b).

 

(h)          “ Conversion Shares ” means the number of shares of Common Stock issuable upon conversion of Series I Preferred Stock.

 

(i)          “ Convertible Securities ” means any convertible securities, preferred stock, warrants, options or other rights to subscribe for or to purchase or exchange for, shares of Common Stock.

 

(j)          “ Dilutive Issuance ” shall have the meaning set forth in Section 7(b)

 

(k)         “ Dilutive Issuance Notice ” shall have the meaning set forth in Section 7(b).

 

(l)          “ Dividend Issuance ” shall have the meaning set forth in Section 7(c)

 

(m)         “ Dividend Issuance Notice ” shall have the meaning set forth in Section 7(c).

 

(n)         “ Exempt Issuance ” means the issuance of (a) shares of Common Stock or options to employees, consultants, officers or directors of the Corporation pursuant to (i) any stock or option plan duly adopted by a majority of the non-employee members of the Board of the Corporation or a majority of the members of a committee of non-employee directors established for such purpose or (ii) employment agreements with Corporation employees, (b) securities upon the exercise or exchange of or conversion of Convertible Securities outstanding as of the date of first issuance of any shares of Series I Preferred Stock, provided that such securities are not amended subsequent to the date of first issuance of any shares of Series I Preferred Stock to increase the number of such securities or to decrease the exercise, exchange or conversion price of any such securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors, provided any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating company in, or an individual that operates, a business synergistic with the business of the Corporation and in which the Corporation receives benefits in addition to the investment of funds, but shall not include a transaction in which the Corporation is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (d) up to a maximum of 10,000,000 shares of Common Stock or Common Stock equivalents in any rolling 12 month period issued to consultants, vendors, financial institutions or lessors in connection with services provided by such Persons referred to in this clause (d), but shall not include a transaction in which the Corporation is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and provided that none of such shares may be registered for sale or resale by any of such holders; (e) securities issued as dividends payable upon any shares of Corporation Preferred Stock issued and outstanding as of the date of first issuance of any shares of Series I Preferred Stock; and (f) securities issued in connection with any stock split, stock dividend or recapitalization of the Common Stock.

 

(o)          “ Existing Preferred Stock ” means, as of any date of determination, the then issued and outstanding shares of Series C Preferred Stock.

 

8
 

 

(p)          ““ Issuable Maximum ” means: (a) for purposes of Section 4(c)(i) a number of shares of Common Stock equal to 19.99% of the of the Corporation's outstanding shares on the date of first issuance of any shares of Series I Preferred Stock; and (b) for purposes of Section 4(c)(ii) the balance of authorized shares of Common Stock that are not issued, outstanding or reserved for issuance.

 

(q)          “ Person ” means any individual, corporation, partnership, limited liability company, joint venture, trust, business association, organization or other entity.

 

(r)           “ Shareholder Approval ” means (a) for purposes of Section 4(c)(i), the vote of Corporation shareholders, if and as may be required by the applicable rules and regulations of the Corporation’s Trading Market (or any successor entity) to approve the issuance of shares of Common Stock in excess of the Issuable Maximum; and (b) for purposes of Section 4(c)(ii), the vote of Corporation shareholders, as may be required by Nevada law to approve an increase in the number of authorized shares of Common Stock in excess of the Issuable Maximum without a corresponding decrease in the par value thereof.

 

(s)          " Stated Value ” shall have the meaning set forth in Section 1.

 

(t)          “ Subsidiary ” means Elite Laboratories, Inc., a Delaware corporation.

 

(u)          “ Trading Days ” means any day that the Trading Market upon which the Common Stock trades or is quoted is open.

 

(v)         “ Trading Market ” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: (a) the following “ National Markets ”: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or (b) the OTC Bulletin Board (or any successors to any of the foregoing).

 

[Signature page follows]

 

9
 

 

IN WITNESS WHEREOF , this Certificate of Designation is executed on behalf of the Corporation as of February 6, 2014.

 

  ELITE PHARMACEUTICALS, INC.
   
  s/ Nasrat Hakim
  Nasrat Hakim, CEO

 

10
 

 

ANNEX A

 

CONVERSION NOTICE

 

(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES I PREFERRED STOCK)

 

The undersigned hereby elects to convert the number of shares of Series I Convertible Preferred Stock indicated below into shares of common stock, par value US$0.001 per share (the “Common Stock”), of Elite Pharmaceuticals Inc., a Nevada corporation (the “Corporation”), according to the conditions hereof, as of the date written below. If shares are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required by the Corporation. No fee will be charged to the Holder for any conversion, except for any such transfer taxes.

 

Date to Effect Conversion :  
     
Number of shares of Series I Preferred Stock owned prior to conversion         :  
     
Number of shares of Series I Preferred Stock to be converted :  
     
Stated Value of shares of Series I Preferred Stock to be converted :  

  

   
Number of shares of Common Stock to be issued :  
     
Applicable Conversion Price :  
     
Number of shares of Series I Preferred Stock subsequent to Conversion :  

 

  [HOLDER]
   
  By:  
     
  Name:  

 

11

 

NUMBER   SHARES
     

 

ELITE PHARMACEUTICALS, INC.

incorporated under the laws of the state of nevada

 

SERIES I CONVERTIBLE PREFERRED STOCK

 

THIS CERTIFIES THAT                                                              is the record holder of                                 FULLY PAID AND NON-ASSESSABLE SHARES OF SERIES I CONVERTIBLE PREFERRED STOCK, $0.01 PAR VALUE, OF ELITE PHARMACEUTICALS, INC. (the “Corporation”), transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certificate and the shares represented hereby are subject to the laws of the State of Nevada, and to the Articles of Incorporation (the “Certificate of Incorporation”), the Certificate of Designations of Preferences, Rights and Limitations of Series I Convertible Preferred Stock (the “Certificate of Designations”) and the By-Laws of the Corporation, as now or hereafter amended, to all of which the holder of this certificate, by acceptance hereof, assents. The SECURITIES EVIDENCED by this certificate have not been registered under the Securities Act of 1933 (the "Act") and cannot be sold or offered for sale or otherwise transferred except pursuant to an effective Registration Statement under the Act or pursuant to an exemption therefrom, the availability of which is to be established to the reasonable satisfaction of the Corporation. The shares represented by this certificate are convertible into shares of Common Stock of the Corporation in the manner as set forth in the Certificate of Designations. The powers, preferences, rights, limitations and restrictions of the Series I Convertible Preferred Stock are set forth in the Certificate of Designation which has been filed with the Secretary of State of the State of Nevada, a copy of which is on file at the office of the Corporation. The Corporation shall furnish without charge to the record holder of this certificate upon written request by such holder, copies of the Certificate of Designations, the Certificate of Incorporation and the By-Laws, as well as the document or documents setting forth the powers, preferences and rights of each of the other classes of the Corporation's stock or series thereof and the qualifications, limitations or restrictions of such preferences or such rights. This certificate is not valid unless signed by its respective officers as set forth below.

 

Dated:                           

 

         
Secretary   [CORPORATE SEAL]   Chief Operating Officer

 

 
 

 

The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations:

 

TEN COM as tenants in common UNIF GIFT MIN ACT   Custodian  
TEN ENT as tenants by the entireties   (Cust)   (Minor)
JT TEN as joint tenants with right   under Uniform Gifts to Minor Act    _________
  of survivorship and not as       (State)     
  tenants in common        

 

Additional abbreviations may also be used though not in the above list.

 

For value received,                                                                                                                                                   hereby sell(s), assign(s) and transfer(s) unto

 

PLEASE INSERT SOCIAL SECURITY OR OTHER

IDENTIFYING NUMBER          OF ASSIGNEE

 

                                    

|                                     |

 

 

 

(Please print or typewrite name and address including postal zip code of assignee)

 

 

 

 

 

                                 Shares of the Series I Convertible Preferred Stock represented by the within Certificate, and do(es) hereby irrevocably constitute and appoint                        Attorney to transfer the said stock on the books of the within-named Corporation with full power of substitution in the premises.

 

Dated:                         

 

     
  NOTICE:   The signature(s) to this assignment must correspond with the name(s) as written upon the face of the Certificate, in every particular, without alteration or enlargement, or any change whatever.

 

Signature(s) Guaranteed:

 

   

THE SIGNAUTRE(S) AS GUARANTEED BY AN ELIGIBLE GUARANTOR

INSTITUION (BANKS, SOTCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS

AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE

GUARANTEE MEDALLION PROGRAM) PURSUANT TO S.E.C. RULE 17Ad-15.

 

 

 

 

AMENDMENT

TO THE AUGUST 1, 2013 SECURED CONVERTIBLE NOTE

TO MIKAH PHARMA LLC

DUE AUGUST 1, 2016 IN THE PRINCIPAL AMOUNT OF $10,000,000

 

This Amendment, dated as of February 7, 2014 (the “Amendment”), by and between Elite Pharmaceuticals, Inc., a corporation organized under the laws of the State of Nevada, and its wholly-owned subsidiary, Elite Laboratories, Inc., a corporation organized under the laws of the State of Delaware (collectively, the “Company”), and Mikah Pharma LLC, a limited liability company organized under the laws of the State of Delaware (“Holder” and along with the Company, the “Parties”), to that certain August 1, 2013 Secured Convertible Note from the Company to Holder due August 1, 2016 in the principal amount of $10,000,000 (the “Note”);

 

WHEREAS the Company and Holder desire to amend the Note on the terms and subject to the conditions contained herein; and

 

WHEREAS , pursuant to section 14(f) of the Note, the Note may be amended by the Parties in a writing executed by both Parties;

 

NOW, THEREFORE in consideration of the mutual covenants and agreements contained herein and in the Note, the sufficiency, adequacy and satisfaction of which are hereby acknowledged, the Parties hereby agree as follows:

 

1.          All capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Note.

 

2.          Section one is amended as follows:

 

(a)          The following definition is added: “’ Series I Preferred ’ means shares of the Company’s Series I Preferred Stock, $0.001 par value.”

 

(b)          The definition of “ Conversion Price ” is amended in its entirety and now reads as follows:

“’Conversion Price’ means $0.07 if converted into shares of Common Stock and $100,000.00 if converted into shares of Series I Preferred, subject to adjustment from time to time pursuant to Section 10.”

 

(c)          The definition of “ Conversion Shares ” is amended in its entirety and now reads as follows:

“’ Conversion Shares ’ means shares of Common Stock and Series I Preferred issuable to holder upon Conversion.

 

(d)          The definition of “ Excluded Stock ” is amended to add the following subsection (h) thereto: “(h) the issuance of any shares of Series I Preferred or the issuance of any Common Stock upon the conversion of any shares of Series I Preferred.”

 

 
 

 

(e)          The definition of “ Issuable Maximum ” is amended in its entirety and now reads as follows: “ Issuable Maximum ” means for purposes of Section 6(b)(i) a number of shares of Common Stock equal to 19.99% of the of the Company's outstanding shares on the Original Issue Date.

 

(f)          The definition of “ Triggering Event ” is amended in its entirety and now reads as follows: “ Triggering Event ” means any of the following events: (a) the Common Stock is not listed or quoted, or is suspended from trading, on a Trading Market for a period of five or more Trading Days (which need not be consecutive Trading Days); (b) subject to subsection (c) below, the Company fails to have available a sufficient number of authorized but unissued and otherwise unreserved shares of Common Stock and/or Series I Preferred available to issue the Conversion Shares upon any conversion of this Note; (c) if at any time commencing 30 Trading Days after the Shareholder Approval, any Common Stock issuable pursuant to the Transaction Documents is not listed on a Trading Market; (d) if Shareholder Approval is required, the Company shall have failed to receive the Shareholder Approval within four (4) months of the requirement to obtain such Shareholder Approval; (e) any of the Debtors fails to make any cash payment required under the Transaction Documents and such failure is not cured within fifteen (15) calendar days after notice of such default is first given to such Debtor by the Holder; or (f) any of the Debtors defaults in the timely performance of any other obligation under the Transaction Documents and such default continues uncured for a period of thirty (30) calendar days after the date on which notice of such default is first given to such Debtor by the Holder (it being understood that no prior notice need be given in the case of a default that cannot reasonably be cured within such thirty (30) days).”

 

3.          Section 3 is amended in its entirety and now reads as follows:

 

“3. Covenants .

 

(a)          Except to the extent that Shareholder Approval is required by Section 6(b) , the Company covenants that it will at all times reserve and keep available out of its authorized but unissued and otherwise unreserved Common Stock and Series I Preferred, solely for the purpose of enabling it to issue Conversion Shares as required hereunder, the number of Conversion Shares which are then issuable and deliverable upon the conversion of (and otherwise in respect of) this entire Note (taking into account the adjustments set forth in Section 10 ), free from preemptive rights or any other contingent purchase rights of Persons other than the Holder. The Company covenants that all Conversion Shares so issuable and deliverable shall, upon issuance in accordance with the terms hereof, be duly and validly authorized and issued and fully paid and nonassessable.”

 

2
 

 

4.          Section 6 is amended in its entirety and now reads as follows:

 

“(a)           At the Option of the Holder . All or any portion of the principal of this Note shall be convertible into shares of Common Stock and/or Series I Preferred (subject to the limitations set forth in Section 6(b) ), at the option of the Holder, at any time, and from time to time, from and after the Original Issue Date. The number of Conversion Shares issuable upon any conversion hereunder shall equal the outstanding principal amount of this Note to be converted, divided by the Conversion Price. The Holder shall effect conversions under this Section 6(a) by delivering to the Company a Conversion Notice together with a schedule in the form of Schedule 2 attached hereto (the “ Conversion Schedule ”). If the Holder is converting less than all of the principal amount of this Note, or if a conversion hereunder may not be effected in full due to the application of Section 6(b) , the Company shall honor such conversion to the extent permissible hereunder and shall promptly deliver to the Holder a Conversion Schedule indicating the principal amount which has not been converted.

 

(b)           Conversion Restrictions . Anything set forth herein to the contrary notwithstanding:

 

(i)          If the Company is listed on a Trading Market that is a National Market and the Company has not previously obtained Shareholder Approval, and such National Market requires Shareholder Approval then the Company may not issue in excess of the Issuable Maximum upon conversions of the Notes. If on any Conversion Date: (A) the aggregate number of shares of Common Stock that would then be issuable upon conversion in full of the then outstanding principal amount of Note would exceed the Issuable Maximum, and (B) the Company shall not have previously obtained Shareholder Approval, then the Company shall issue to the converting Holder a number of shares of Common Stock up to the Issuable Maximum. The Company and the Holder understand and agree that shares of Common Stock issued to and then held by the Holder as a result of conversions of the Note shall not be entitled to cast votes on any resolution to obtain Shareholder Approval pursuant hereto.

 

(c)           Mandatory Conversion . Notwithstanding any other provision of this Note to the contrary, if, on the date (the “ Mandatory Conversion Date ”) any payment under this Note is due and payable whether on the date on which the obligations under the Note mature or by acceleration, redemption, prepayment or otherwise other than as a result of a Bankruptcy Event (a “ Payment ”), the Market Price of the Common Stock is below $0.15 (as adjusted for any stock split, stock dividend or recapitalization of the Common Stock), any such Payment shall automatically be converted into Common Stock at the Conversion Price. If there is not a sufficient number of authorized shares of Common Stock that are not issued, outstanding or reserved for issuance to permit full conversion of the payment under this Subsection 6(c) (such insufficient number of shares of Common Stock, the “ Balance Shares ”), the Company shall issue to the Holder, in lieu of the Balance Shares such number of Series I Preferred as would be convertible into the Balance Shares.”

 

5.          Section 8(b) is amended in its entirety and now read as follows: “(b) Upon the occurrence of any Bankruptcy Event, all amounts due and owing under this Note shall immediately become due and payable in full in cash and not in Common Stock or Series I Preferred, without any further action by the Holder.

 

6.          Schedule 1 is amended in its entirety and now reads as set forth on Schedule 1 attached hereto.

 

3
 

 

7.          Except for the changes to the Note contained in this Amendment, All other terms of the Note are unchanged and remain in full force and effect.

 

(The remainder of this page has been intentionally left blank.)

 

4
 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized representatives as of the day and year first above written.

 

ELITE PHARMACEUTICALS, INC.   ELITE LABORATORIES, INC.
     
By: s/ Carter Ward   By: s/ Carter Ward
  Carter Ward, Chief Financial Officer     Carter Ward, Chief Financial Officer
       
MIKAH PHARMA LLC      
       
By: s/ Nasrat Hakim      
  Nasrat Hakim, Manager      

 

5
 

 

Schedule 1

 

FORM OF CONVERSION NOTICE

 

(To be executed by the registered Holder

in order to convert a Convertible Note)

 

TO: ELITE PHARMACEUTICALS, INC.

  

Re: Secured Convertible Note due 2016 (this “ Note ”) issued by Elite Pharmaceuticals, Inc. and Elite Laboratories, Inc. to Mikah Pharma LLC on or about August 1, 2013 in the original principal amount of $10,000,000 as amended.

 

The undersigned hereby elects to convert the aggregate principal amount indicated below of this Note into shares of common stock, par value $0.001 per share (the “ Common Stock ”) and/or shares of Series I Preferred Stock, par value $0.01 per share (the “ Series I Preferred ”), of Elite Pharmaceuticals, Inc., a Nevada corporation (the “ Corporation ”), according to the conditions hereof, as of the date written below.

 

Date of Conversion:  
Aggregate Principal Amount of Note Being Converted:  
Number of Shares of Common Stock to be Issued:  
Number of Shares of Series I Preferred to be Issued:  
Applicable Conversion Price:  
 
   
   
Authorization:  
  By:  
  Name:  
Dated:  
   
   

 

 
 

 

ACKNOWLEDGEMENT

 

The Corporation hereby acknowledges this Conversion Notice and hereby directs American Stock Transfer & Trust Company to issue the above indicated number of shares of Common Stock.

 

  ELITE PHARMACEUTICALS, INC.
   
  By:  
  Name:  
  Title:  

  

- 7 -

 

 

AMENDMENT

TO THE NOVEMBER 21, 2013 SECURED CONVERTIBLE NOTE

TO JERRY TREPPEL

DUE NOVEMBER 21, 2016 IN THE PRINCIPAL AMOUNT OF $600,000

 

This Amendment, dated as of February 7, 2014 (the “Amendment”), by and between Elite Pharmaceuticals, Inc., a corporation organized under the laws of the State of Nevada, and its wholly-owned subsidiary, Elite Laboratories, Inc., a corporation organized under the laws of the State of Delaware (collectively, the “Company”), and Jerry Treppel (“Holder” and along with the Company, the “Parties”), to that certain November 21, 2013 Secured Convertible Note from the Company to Holder due November 21, 2016 in the principal amount of $600,000 (the “Note”);

 

WHEREAS the Company and Holder desire to amend the Note on the terms and subject to the conditions contained herein; and

 

WHEREAS , pursuant to section 14(f) of the Note, the Note may be amended by the Parties in a writing executed by both Parties;

 

NOW, THEREFORE in consideration of the mutual covenants and agreements contained herein and in the Note, the sufficiency, adequacy and satisfaction of which are hereby acknowledged, the Parties hereby agree as follows:

 

1.         All capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Note.

 

2.         Section one is amended as follows:

 

(a)          The following definition is added: “’ Series I Preferred ’ means shares of the Company’s Series I Preferred Stock, $0.001 par value.”

 

(b)          The definition of “ Conversion Price ” is amended in its entirety and now reads as follows:

“’Conversion Price’ means $0.099 if converted into shares of Common Stock and $141,442.7157 if converted into shares of Series I Preferred, subject to adjustment from time to time pursuant to Section 10.”

 

(c)          The definition of “ Conversion Shares ” is amended in its entirety and now reads as follows:

“’ Conversion Shares ’ means shares of Common Stock and Series I Preferred issuable to holder upon Conversion.

 

(d)          The definition of “ Excluded Stock ” is amended to add the following subsection (h) thereto: “(h) the issuance of any shares of Series I Preferred or the issuance of any Common Stock upon the conversion of any shares of Series I Preferred.”

 

 
 

 

(e)          The definition of “ Issuable Maximum ” is amended in its entirety and now reads as follows: “ Issuable Maximum ” means for purposes of Section 6(b)(i) a number of shares of Common Stock equal to 19.99% of the of the Company's outstanding shares on the Original Issue Date.

 

(f)          The definition of “ Triggering Event ” is amended in its entirety and now reads as follows: “ Triggering Event ” means any of the following events: (a) the Common Stock is not listed or quoted, or is suspended from trading, on a Trading Market for a period of five or more Trading Days (which need not be consecutive Trading Days); (b) subject to subsection (c) below, the Company fails to have available a sufficient number of authorized but unissued and otherwise unreserved shares of Common Stock and/or Series I Preferred available to issue the Conversion Shares upon any conversion of this Note; (c) if at any time commencing 30 Trading Days after the Shareholder Approval, any Common Stock issuable pursuant to the Transaction Documents is not listed on a Trading Market; (d) if Shareholder Approval is required, the Company shall have failed to receive the Shareholder Approval within four (4) months of the requirement to obtain such Shareholder Approval; (e) any of the Debtors fails to make any cash payment required under the Transaction Documents and such failure is not cured within fifteen (15) calendar days after notice of such default is first given to such Debtor by the Holder; or (f) any of the Debtors defaults in the timely performance of any other obligation under the Transaction Documents and such default continues uncured for a period of thirty (30) calendar days after the date on which notice of such default is first given to such Debtor by the Holder (it being understood that no prior notice need be given in the case of a default that cannot reasonably be cured within such thirty (30) days).”

 

3.            Section 3 is amended in its entirety and now reads as follows:

 

“3.   Covenants .

 

(a)       Except to the extent that Shareholder Approval is required by Section 6(b) , the Company covenants that it will at all times reserve and keep available out of its authorized but unissued and otherwise unreserved Common Stock and Series I Preferred, solely for the purpose of enabling it to issue Conversion Shares as required hereunder, the number of Conversion Shares which are then issuable and deliverable upon the conversion of (and otherwise in respect of) this entire Note (taking into account the adjustments set forth in Section 10 ), free from preemptive rights or any other contingent purchase rights of Persons other than the Holder. The Company covenants that all Conversion Shares so issuable and deliverable shall, upon issuance in accordance with the terms hereof, be duly and validly authorized and issued and fully paid and nonassessable.”

 

2
 

 

 

4.            Section 6 is amended in its entirety and now reads as follows:

 

“(a)      At the Option of the Holder . All or any portion of the principal of this Note shall be convertible into shares of Common Stock and/or Series I Preferred (subject to the limitations set forth in Section 6(b) ), at the option of the Holder, at any time, and from time to time, from and after the Original Issue Date. The number of Conversion Shares issuable upon any conversion hereunder shall equal the outstanding principal amount of this Note to be converted, divided by the Conversion Price. The Holder shall effect conversions under this Section 6(a) by delivering to the Company a Conversion Notice together with a schedule in the form of Schedule 2 attached hereto (the “ Conversion Schedule ”). If the Holder is converting less than all of the principal amount of this Note, or if a conversion hereunder may not be effected in full due to the application of Section 6(b) , the Company shall honor such conversion to the extent permissible hereunder and shall promptly deliver to the Holder a Conversion Schedule indicating the principal amount which has not been converted.

 

(b)        Conversion Restrictions . Anything set forth herein to the contrary notwithstanding:

 

(i)          If the Company is listed on a Trading Market that is a National Market and the Company has not previously obtained Shareholder Approval, and such National Market requires Shareholder Approval then the Company may not issue in excess of the Issuable Maximum upon conversions of the Notes. If on any Conversion Date: (A) the aggregate number of shares of Common Stock that would then be issuable upon conversion in full of the then outstanding principal amount of Note would exceed the Issuable Maximum, and (B) the Company shall not have previously obtained Shareholder Approval, then the Company shall issue to the converting Holder a number of shares of Common Stock up to the Issuable Maximum. The Company and the Holder understand and agree that shares of Common Stock issued to and then held by the Holder as a result of conversions of the Note shall not be entitled to cast votes on any resolution to obtain Shareholder Approval pursuant hereto.

 

(c)        Mandatory Conversion . Notwithstanding any other provision of this Note to the contrary, if, on the date (the “ Mandatory Conversion Date ”) any payment under this Note is due and payable whether on the date on which the obligations under the Note mature or by acceleration, redemption, prepayment or otherwise other than as a result of a Bankruptcy Event (a “ Payment ”), the Market Price of the Common Stock is below $0.15 (as adjusted for any stock split, stock dividend or recapitalization of the Common Stock), any such Payment shall automatically be converted into Common Stock at the Conversion Price. If there is not a sufficient number of authorized shares of Common Stock that are not issued, outstanding or reserved for issuance to permit full conversion of the payment under this Subsection 6(c) (such insufficient number of shares of Common Stock, the “ Balance Shares ”), the Company shall issue to the Holder, in lieu of the Balance Shares such number of Series I Preferred as would be convertible into the Balance Shares.”

 

5.         Section 8(b) is amended in its entirety and now read as follows: “(b) Upon the occurrence of any Bankruptcy Event, all amounts due and owing under this Note shall immediately become due and payable in full in cash and not in Common Stock or Series I Preferred, without any further action by the Holder.

 

6.         Schedule 1 is amended in its entirety and now reads as set forth on Schedule 1 attached hereto.

 

3
 

 

7.         Except for the changes to the Note contained in this Amendment, All other terms of the Note are unchanged and remain in full force and effect.

 

(The remainder of this page has been intentionally left blank.)

 

4
 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized representatives as of the day and year first above written.

 

  ELITE PHARMACEUTICALS, INC.     ELITE LABORATORIES, INC.
         
By: s/ Carter Ward   By: s/ Carter Ward
  Carter Ward, Chief Financial Officer     Carter Ward, Chief Financial Officer
         
By: s/ Jerry Treppel      
  Jerry Treppel      

 

5
 

 

Schedule 1

 

FORM OF CONVERSION NOTICE

 

(To be executed by the registered Holder

in order to convert a Convertible Note)

 

TO:        ELITE PHARMACEUTICALS, INC.

 

Re: Secured Convertible Note due 2016 (this “ Note ”) issued by Elite Pharmaceuticals, Inc. and Elite Laboratories, Inc. to Jerry Treppel on or about November 21, 2013 in the original principal amount of $600,000 as amended.

 

The undersigned hereby elects to convert the aggregate principal amount indicated below of this Note into shares of common stock, par value $0.001 per share (the “ Common Stock ”) and/or shares of Series I Preferred Stock, par value $0.01 per share (the “ Series I Preferred ”), of Elite Pharmaceuticals, Inc., a Nevada corporation (the “ Corporation ”), according to the conditions hereof, as of the date written below.

 

Date of Conversion:  
Aggregate Principal Amount of Note Being Converted:  
Number of Shares of Common Stock to be Issued:  
Number of Shares of Series I Preferred to be Issued:  
Applicable Conversion Price:  

 

   
Authorization:    
  By:  
  Name:  
Dated:    
   
   
   

 

 
 

 

ACKNOWLEDGEMENT

 

The Corporation hereby acknowledges this Conversion Notice and hereby directs American Stock Transfer & Trust Company to issue the above indicated number of shares of Common Stock.

 

  ELITE PHARMACEUTICALS, INC.
   
  By:  
  Name:  
  Title:  

 

- 7 -